AP1246A - Substituted pyrazoles as p38 Kinase inhibitors. - Google Patents

Substituted pyrazoles as p38 Kinase inhibitors.

Info

Publication number
AP1246A
AP1246A APAP/P/1999/001715A AP9901715A AP1246A AP 1246 A AP1246 A AP 1246A AP 9901715 A AP9901715 A AP 9901715A AP 1246 A AP1246 A AP 1246A
Authority
AP
ARIPO
Prior art keywords
kinase inhibitors
substituted pyrazoles
pyrazoles
substituted
class
Prior art date
Application number
APAP/P/1999/001715A
Other versions
AP9901715A0 (en
Inventor
Ashok Anantanarayan
Michael Clare
Paul W Collins
Joyce Zuowu Crich
Rajesh Devraj
Daniel L Flynn
Lifeng Geng
Gunnar J Hanson
Francis J Koszyk
Shuyuan Liao
Richard A Partis
Shashidhar N Rao
Shaun Raj Selness
Michael J South
Michael A Stealey
Richard M Weier
Xiangdong Xu
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of AP9901715A0 publication Critical patent/AP9901715A0/en
Application granted granted Critical
Publication of AP1246A publication Critical patent/AP1246A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

A class of pyrazole derivatives is described for use in treating p38 kinase mediated disorders. Compounds of particular interest are defined by formula (i)wherein r1, r2, r3 and r4 are as described in the specification
APAP/P/1999/001715A 1997-05-22 1998-05-22 Substituted pyrazoles as p38 Kinase inhibitors. AP1246A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4757097P 1997-05-22 1997-05-22
PCT/US1998/010436 WO1998052940A1 (en) 1997-05-22 1998-05-22 SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS

Publications (2)

Publication Number Publication Date
AP9901715A0 AP9901715A0 (en) 1999-12-31
AP1246A true AP1246A (en) 2004-02-07

Family

ID=21949743

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1999/001715A AP1246A (en) 1997-05-22 1998-05-22 Substituted pyrazoles as p38 Kinase inhibitors.

Country Status (24)

Country Link
EP (1) EP1000055A1 (en)
JP (1) JP2002508754A (en)
KR (1) KR20010012854A (en)
CN (1) CN1264377A (en)
AP (1) AP1246A (en)
AU (1) AU754830C (en)
BG (1) BG64313B1 (en)
BR (1) BR9809147A (en)
CA (1) CA2291115A1 (en)
EA (1) EA003925B1 (en)
EE (1) EE9900527A (en)
GE (1) GEP20033053B (en)
HU (1) HUP0001880A3 (en)
ID (1) ID22982A (en)
IL (1) IL132991A (en)
IS (1) IS5257A (en)
NO (1) NO995695L (en)
NZ (1) NZ501112A (en)
OA (1) OA12981A (en)
PL (1) PL337020A1 (en)
SK (1) SK157899A3 (en)
TR (1) TR200000235T2 (en)
WO (1) WO1998052940A1 (en)
ZA (1) ZA984358B (en)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW289752B (en) * 1994-03-11 1996-11-01 Ciba Geigy Ag
US5559137A (en) * 1994-05-16 1996-09-24 Smithkline Beecham Corp. Compounds
US6979686B1 (en) 2001-12-07 2005-12-27 Pharmacia Corporation Substituted pyrazoles as p38 kinase inhibitors
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
AU7726898A (en) 1997-05-22 1998-12-11 G.D. Searle & Co. Pyrazole derivatives as p38 kinase inhibitors
JP2002504909A (en) 1997-06-13 2002-02-12 スミスクライン・ビーチャム・コーポレイション New substituted pyrazole and pyrazoline compounds
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
US6649617B1 (en) 1998-10-07 2003-11-18 Smithkline Beecham Corporation Treatment for stroke management
US6548503B1 (en) 1998-11-04 2003-04-15 Smithkline Beecham Corporation Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines
DE69903976T2 (en) 1998-12-16 2003-07-24 Aventis Pharma Ltd HETEROARYL CYCLIC ACETALS
US6191147B1 (en) 1998-12-24 2001-02-20 Ppd Discovery, Inc. Pyrazole compounds and uses thereof
WO2000039116A1 (en) * 1998-12-25 2000-07-06 Teikoku Hormone Mfg. Co., Ltd. Aminopyrazole derivatives
JP4832647B2 (en) 1999-03-26 2011-12-07 ユーロ−セルティック エス． ア． Aryl-substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles and their use
US6667325B1 (en) 1999-06-03 2003-12-23 Teikoku Hormone Mfg. Co., Ltd. Substituted pyrazole compounds
US7122666B2 (en) 1999-07-21 2006-10-17 Sankyo Company, Limited Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
AU6909600A (en) * 1999-08-13 2001-03-13 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
WO2001030154A2 (en) * 1999-10-25 2001-05-03 Basf Aktiengesellschaft Agrochemical compositions containing pyrazoles and use thereof as fungicidal plant protection agents
DE19952147A1 (en) 1999-10-29 2001-05-03 Boehringer Ingelheim Pharma New cyclopropanes, pharmaceutical compositions containing these compounds and process for their preparation
ES2249309T3 (en) 1999-11-23 2006-04-01 Smithkline Beecham Corp COMPOUNDS OF 3,4-DIHIDRO- (1H) QUINAZOLIN-2-ONA AS INHIBITORS OF CSBP / P39 KINASA.
EP1235814B1 (en) 1999-11-23 2004-11-03 Smithkline Beecham Corporation 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/p38 KINASE INHIBITORS
EP1233951B1 (en) 1999-11-23 2005-06-01 SmithKline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
EP1309592B9 (en) 2000-08-14 2007-02-28 Ortho-McNeil Pharmaceutical, Inc. Substituted pyrazoles
GB0102687D0 (en) 2001-02-02 2001-03-21 Pharmacia & Upjohn Spa Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them
CA2437248A1 (en) * 2001-02-02 2002-08-15 Takeda Chemical Industries, Ltd. Jnk inhibitor
DE60227794D1 (en) 2001-04-26 2008-09-04 Eisai R&D Man Co Ltd NITROGENIC COMPOUND WITH CONDENSED RING AND PYRAZOLYL GROUP AS A SUBSTITUENT AND MEDICAL COMPOSITION THEREOF
PL221339B1 (en) 2001-05-24 2016-03-31 Lilly Co Eli Novel pyrrole derivatives as pharmaceutical agents
RU2277534C2 (en) * 2001-09-25 2006-06-10 Фармация Корпорейшн Method for preparing substituted pyrazoles
US7057049B2 (en) 2001-09-25 2006-06-06 Pharmacia Corporation Process for making substituted pyrazoles
PL369497A1 (en) 2001-09-25 2005-04-18 Pharmacia Corporation Process for making substituted pyrazoles
AR040442A1 (en) * 2002-06-05 2005-04-06 Pharmacia Corp DERIVATIVES OF PIRAZOL AS INHIBITORS OF QUINASA P38
GB0215844D0 (en) 2002-07-09 2002-08-14 Novartis Ag Organic compounds
CA2492033A1 (en) 2002-07-09 2004-01-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
GB0217786D0 (en) * 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
US6649638B1 (en) 2002-08-14 2003-11-18 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
EP1534680B1 (en) 2002-08-14 2012-02-22 Pharmaco Investments, Inc. Prenylation inhibitors and methods of their synthesis and use
AU2003268155A1 (en) * 2002-09-19 2004-04-08 Eli Lilly And Company Methods of inhibiting tgf beta with substituted pyrazoles
GB0229618D0 (en) * 2002-12-19 2003-01-22 Cancer Rec Tech Ltd Pyrazole compounds
EP1591443B1 (en) 2003-02-07 2010-08-25 Daiichi Sankyo Company, Limited Pyrazole derivative
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
DE602005010714D1 (en) 2004-08-12 2008-12-11 Pfizer THE P38 MAP KINASE
PE20060777A1 (en) 2004-12-24 2006-10-06 Boehringer Ingelheim Int INDOLINONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
KR101181692B1 (en) 2004-12-28 2012-09-19 아스카 세이야쿠 가부시키가이샤 Pyrimidinylisoxazol derivative
CA2643066A1 (en) * 2006-03-16 2007-09-20 Pfizer Products Inc. Pyrazole compounds
CN101478989A (en) 2006-06-28 2009-07-08 Aska制药株式会社 Treatment agent for inflammatory bowel disease
US8207203B2 (en) 2006-06-28 2012-06-26 Aska Pharmaceutical Co., Ltd. Pyridylisoxazole derivatives
CN101610754A (en) 2007-02-16 2009-12-23 Aska制药株式会社 Pharmaceutical composition containing microparticle oily suspension
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
EP2181110A2 (en) * 2007-07-13 2010-05-05 ADDEX Pharma S.A. Novel heteroaromatic derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
US8859580B2 (en) 2007-11-16 2014-10-14 Boehringer Ingelheim International Gmbh Aryl- and heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use
CL2009000904A1 (en) * 2008-04-21 2010-04-30 Shionogi & Co Compounds derived from cyclohexyl sulfonamides having antagonist activity at the npy y5 receptor, pharmaceutical composition and pharmaceutical formulation comprising them.
TW200950780A (en) 2008-05-13 2009-12-16 Boehringer Ingelheim Int Alicyclic carboxylic acid derivatives of benzomorphans and related scaffolds, medicaments containing such compounds and their use
CN102105459B (en) 2008-07-24 2014-09-10 内尔维阿诺医学科学有限公司 3,4-diarylpyrazoles as protein kinase inhibitors
JP5586605B2 (en) * 2008-08-25 2014-09-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Aryl and heteroarylcarbonyl derivatives of substituted nortropanes, medicaments containing said compounds and uses thereof
JP2012506388A (en) * 2008-10-23 2012-03-15 ロンザ リミテッド Method for the synthesis of substituted pyrazoles
ES2549005T3 (en) * 2008-11-21 2015-10-22 Raqualia Pharma Inc New pyrazole-3-carboxamide derivative that has 5-HT2B receptor antagonist activity
JP5670440B2 (en) 2009-06-02 2015-02-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Cyclic inhibitor of 11β-hydroxysteroid dehydrogenase 1
EP2440537A1 (en) 2009-06-11 2012-04-18 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 based on the 1,3 -oxazinan- 2 -one structure
CA2771936A1 (en) * 2009-08-26 2011-03-03 Novartis Ag Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators
AR077975A1 (en) 2009-08-28 2011-10-05 Irm Llc PIRAZOL PYRIMIDINE DERIVATIVES AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
EP2308866A1 (en) 2009-10-09 2011-04-13 Bayer CropScience AG Phenylpyri(mi)dinylpyrazoles and their use as fungicides
CN102762551A (en) 2009-12-21 2012-10-31 拜尔农作物科学股份公司 Thienylpyri (mi) dinylpyrazoles and their use for controlling phytopathogenic fungi
EA023942B1 (en) 2010-01-27 2016-07-29 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors
AR081810A1 (en) 2010-04-07 2012-10-24 Bayer Cropscience Ag BICYCLE PIRIDINYL PIRAZOLS
EP2582698B1 (en) 2010-06-16 2016-09-14 Vitae Pharmaceuticals, Inc. Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
CN103153980B (en) 2010-08-03 2015-12-16 内尔维安诺医学科学有限公司 The derivative of pyrazolo phenyl benzenesulfonamides compound and the purposes as antitumour drug thereof
RS59098B1 (en) * 2010-12-20 2019-09-30 Pfizer Novel fused pyridine compounds as casein kinase inhibitors
WO2012175513A1 (en) 2011-06-20 2012-12-27 Bayer Intellectual Property Gmbh Thienylpyri(mi)dinylpyrazole
US8735585B2 (en) 2011-08-17 2014-05-27 Boehringer Ingelheim International Gmbh Indenopyridine derivatives
WO2013050434A1 (en) 2011-10-06 2013-04-11 Bayer Intellectual Property Gmbh Heterocyclylpyri(mi)dinylpyrazole
RU2616293C2 (en) 2011-10-06 2017-04-14 Байер Интеллектуэль Проперти Гмбх Geterocyclilpyridinylpyrazols as fungicidal agents
DE102011115525A1 (en) 2011-10-11 2013-04-11 Boehringer Ingelheim International Gmbh Two-part bottle packaging device for containing pharmaceutical tablets or capsules, has bottle body and bottle base, where bottle is closed with pressure lock or with pressure lock injected at bottle body or with separate rotary lock
CN108542906A (en) 2011-11-11 2018-09-18 诺华股份有限公司 The method for treating proliferative disease
UA115039C2 (en) 2011-11-23 2017-09-11 Еррей Біофарма Інк. Pharmaceutical formulations
EP2968330B1 (en) 2013-03-15 2021-09-29 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
WO2015088038A1 (en) * 2013-12-12 2015-06-18 住友化学株式会社 Aromatic compound and application for same
CN104829536B (en) * 2015-05-04 2017-12-29 陕西科技大学 A kind of Phenylpyrazole carboxylic acid compound and its synthetic method for having antitumor activity
ES2791340T3 (en) * 2015-05-27 2020-11-03 Kyorin Seiyaku Kk Derived from urea or pharmacologically acceptable salt thereof
CN109748873B (en) * 2017-11-08 2021-02-02 北京嘉林药业股份有限公司 Compounds and their use in the treatment of cancer
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
JP2023509452A (en) 2020-01-03 2023-03-08 バーグ エルエルシー Polycyclic Amides as UBE2K Modulators to Treat Cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996003385A1 (en) * 1994-07-21 1996-02-08 G.D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
US5559137A (en) * 1994-05-16 1996-09-24 Smithkline Beecham Corp. Compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2753659B2 (en) * 1990-09-03 1998-05-20 株式会社大塚製薬工場 Pyrazole derivatives
US5593992A (en) * 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
JP3734180B2 (en) * 1994-12-28 2006-01-11 エーザイ株式会社 New pyrazole derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559137A (en) * 1994-05-16 1996-09-24 Smithkline Beecham Corp. Compounds
WO1996003385A1 (en) * 1994-07-21 1996-02-08 G.D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation

Also Published As

Publication number Publication date
CN1264377A (en) 2000-08-23
NZ501112A (en) 2002-10-25
ZA984358B (en) 1999-05-24
PL337020A1 (en) 2000-07-31
AU7588398A (en) 1998-12-11
AP9901715A0 (en) 1999-12-31
KR20010012854A (en) 2001-02-26
SK157899A3 (en) 2000-08-14
HUP0001880A3 (en) 2002-03-28
BG64313B1 (en) 2004-09-30
EP1000055A1 (en) 2000-05-17
IL132991A0 (en) 2001-03-19
BR9809147A (en) 2000-08-01
WO1998052940A1 (en) 1998-11-26
OA12981A (en) 2006-10-13
IS5257A (en) 1999-11-19
EE9900527A (en) 2000-06-15
JP2002508754A (en) 2002-03-19
TR200000235T2 (en) 2000-05-22
BG103964A (en) 2000-08-31
NO995695L (en) 2000-01-21
GEP20033053B (en) 2003-08-25
AU754830C (en) 2004-02-12
EA003925B1 (en) 2003-10-30
IL132991A (en) 2005-11-20
AU754830B2 (en) 2002-11-28
ID22982A (en) 1999-12-23
HUP0001880A2 (en) 2001-03-28
NO995695D0 (en) 1999-11-19
CA2291115A1 (en) 1998-11-26
EA199900953A1 (en) 2000-10-30

Similar Documents

Publication Publication Date Title
AP1246A (en) Substituted pyrazoles as p38 Kinase inhibitors.
AP2001002172A0 (en) Substituted pyrazoles as p38 kinase inhibitors
BR9809451A (en) Pyrazoles substituted with 3 (5) -heteroaryl as inhibitors of p38 kinase.
MY119800A (en) Pyridine derivatives
AU3328499A (en) Phthalazinone pde iii/iv inhibitors
MY133392A (en) Novel substituted pyrazole derivatives
IL127877A (en) Pyrazole derivatives
PL327735A1 (en) Novel substituted derivatives of imidazole
MXPA02011977A (en) Substituted pyridine herbicides.
MY128485A (en) Pesticidal 1-arylpyrazoles
NZ544591A (en) Pyrrolodihydroisoquinolines as PDE10 inhibitors
DK0772603T3 (en) Substituted pyrimidine compounds and their use
ES2249309T3 (en) COMPOUNDS OF 3,4-DIHIDRO- (1H) QUINAZOLIN-2-ONA AS INHIBITORS OF CSBP / P39 KINASA.
AU1783201A (en) 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
GB0308201D0 (en) Novel compounds
ATE291018T1 (en) PYRAZOLE COMPOUNDS AND THEIR USES
PT920426E (en) NEW TIAZOLE DERIVATIVES WITH PHOSPHODIESTERASE INHIBITOR EFFECT
AU2001263278A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
AU1781601A (en) 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
AP2001002188A0 (en) 5HT1 antagonists for antidepressant therapy.
MX9702203A (en) Substituted pyrazolyl-pyrazole derivatives, processes for their preparation and their use as agents with herbicidal action.
DE60036558D1 (en) PHTHALAZINONE DERIVATIVES AS PDE 4 HEMMER
AU2001296699A1 (en) Condensed pyrazindione derivatives as pde inhibitors
CA2423357A1 (en) Fused heterocyclic derivatives as phosphodiesterase inhibitors
MY141481A (en) Substituted pyrazoles as p38 kinase inhibitors